Document:

EMPLOYMENT AGREEMENT, Amended and Restated as of April 27, 2007, between REVLON CONSUMER PRODUCTS CORPORATION, a Delaware corporation (“RCPC” and, together with its parent Revlon, Inc. and its subsidiaries, the “Company”), and Robert K. Kretzman (the “Executive”).

RCPC wishes to continue to employ the Executive as Executive Vice President, Human Resources, Chief Legal Officer and General Counsel, and the Executive wishes to accept continued employment with the Company on the terms and conditions set forth in this Agreement, as amended and restated.

Accordingly, RCPC and the Executive hereby agree as follows:

1. Employment, Duties and Acceptance.

1.1 Employment, Duties. RCPC hereby employs the Executive for the Term (as defined in Section 2.1) to render exclusive and full-time services to the Company as chief legal officer and the executive responsible for world-wide legal affairs, human resources, licensing and security of Revlon, Inc. and its subsidiaries, and to perform such other duties consistent therewith as may be assigned to the Executive from time to time. The Executive’s title shall be Executive Vice President, Human Resources, Chief Legal Officer and General Counsel, or such other title of at least equivalent level consistent with the Executive’s duties from time to time as may be assigned to the Executive. The Executive shall be a member of the Operating Committee or such other committee of the Company’s most senior
executives as may succeed the Operating Committee from time to time and report to the President and Chief Executive Officer of Revlon, Inc. or his designee.

1.2 Acceptance. The Executive hereby accepts such employment and agrees to render the services described above. During the Term, the Executive agrees to serve the Company faithfully and to the best of the Executive’s ability, to devote the Executive’s entire business time, energy and skill to such employment, and to use the Executive’s best efforts, skill and ability to promote the Company’s interests.

1.3 Location. The duties to be performed by the Executive hereunder shall be performed primarily at the office of RCPC in the New York City metropolitan area, subject to reasonable travel requirements consistent with the nature of the Executive’s duties from time to time on behalf of the Company.

2. Term of Employment; Certain Post-Term Benefits.

2.1 The Term. The term of the Executive’s employment under this Agreement (the “Term”) shall commence on the date hereof (the “Effective Date”) and shall end on such date as is provided pursuant to Section 2.2. 

2.2 End-of-Term Provisions. At any time during the Term, RCPC shall have the right to give written notice of non-extension of the Term. In the event RCPC gives such notice of non-extension, the Term automatically shall end on the second anniversary of the date on which RCPC give such notice. The giving of such notice shall not be deemed to be a breach of this Agreement by RCPC for purposes of Section 4.4. During any period that the Executive’s employment shall continue following expiration of the Term, the Executive shall be eligible for severance on terms no less favorable than those of the Revlon Executive Severance Policy as in effect on January 1, 2002 (the “Executive Severance Policy”), provided that in no event shall the severance and benefit continuation be less than 24 months, upon
the Executive’s compliance with the terms thereof, and the Executive shall be deemed to be an employee at will.

2.3 Special Curtailment. The Term shall end earlier than the date provided in Section 2.2, if sooner terminated pursuant to Section 4.

3. Compensation; Benefits.

3.1 Salary. As compensation for all services to be rendered pursuant to this Agreement, RCPC agrees to pay the Executive during the Term a base salary, payable in bi-weekly arrears, at the annual rate of not less than that currently in effect on the Effective Date (the “Base Salary”). All payments of Base Salary or other compensation hereunder shall be less such deductions or withholdings as are required by applicable law and regulations. In the event that RCPC, in its sole discretion, from time to time determines to increase the Base Salary, such increased amount shall, from and after the effective date of the increase, constitute “Base Salary” for purposes of this Agreement and shall not thereafter be decreased. 

 

3.2 Bonus. In addition to the amounts to be paid to the Executive pursuant to Section 3.1, the Executive shall be eligible to receive a maximum annual bonus with respect to each year during the Term equal to 100% of Base Salary at the rate or rates in effect during the year for which bonus is earned, with a target bonus equal to 75% of Base Salary, based upon achievement of objectives set annually. Notwithstanding the foregoing, if the Executive’s employment shall end pursuant to Section 4.2 or 4.4 at any time during the Term, the Executive’s bonus with respect to the calendar year in which the termination occurs shall be an amount equal to the bonus that would have been payable to the Executive with respect to such year if the Executive had remained employed to the date for payment of bonuses
under such Plan, multiplied by a fraction of which the numerator is the number of days of the Term during such year and the denominator is 365. Notwithstanding anything herein or contained in the Bonus Plan to the contrary, in the event that the Executive’s employment shall terminate pursuant to Section 4.4 during any calendar year, the Executive shall be entitled to receive the Executive’s bonus (if not already paid) with respect to the year immediately preceding the year of termination (if bonuses with respect to such year are payable to other executives based upon achievement of bonus objectives and not based upon discretionary amounts which may be paid to other executives despite non-achievement of bonus objectives) as and when such

 

 

 

 

 

-2-

 

bonuses would otherwise be payable to executives under the Bonus Plan, despite the fact that Executive may not be actively employed on such date of payment.

3.3 Stock Awards. During the Term, the Executive shall be considered for recommendation to the Compensation Committee or other committee of the Board (the “Compensation Committee”) administering the Second Amended and Restated Revlon, Inc. Stock Plan (or any plan that may replace it) and/or any other long-term incentive compensation plan of the Company as from time to time in effect, for awards of stock options, restricted shares or other awards, at levels and on terms consistent with the Company’s long-term incentive compensation programs and policies as in effect from time to time commensurate with his position as Executive Vice President, Human Resources, Chief Legal Officer and General Counsel of the Company. If the Company shall terminate the Executive’s employment without Cause
pursuant to Section 4.4 or if the Executive shall terminate his employment for Good Reason pursuant to Section 4.4, each option award held by the Executive (collectively, the “Existing Option Awards”) and each restricted share award held by the Executive (collectively, the “Existing Restricted Share Awards” and, together with the Existing Option Awards, the “Existing Equity Awards”), shall (x) in the case of each of the Existing Option Awards, (A) continue to vest in accordance with its terms as if the Executive’s employment had not been terminated and he had remained employed with the Company and (B) remain exercisable until the later of (i) one year after such Existing Option Award becomes 100% fully vested and exercisable or (ii) 18 months following the Executive’s termination of employment with the Company, but in no event beyond the original option term of each such award and (y) in the case of each of the Existing Restricted Share Awards,
continue to vest as if the Executive’s employment had not been terminated and he had remained employed with the Company. Notwithstanding anything to the contrary in this Section 3.3, in the event that any provision for treatment of the Existing Equity Awards in the preceding sentence would trigger liability for interest and additional tax for the Executive under Section 409A (as defined in Section 4.6 below), the Company agrees that this Section 3.3 shall be construed as providing for the continuation of vesting and the extension of post-employment exercisability of such Existing Equity Awards to the fullest extent allowable under Section 409A without triggering such interest or additional tax, provided that in no event shall the Company be required to provide for terms more favorable than set out in the preceding sentence.

3.4 Business Expenses. RCPC shall pay or reimburse the Executive for all reasonable expenses actually incurred or paid by the Executive during the Term in the performance of the Executive’s services under this Agreement, subject to and in accordance with the Company’s applicable expense reimbursement and related policies and procedures as in effect from time to time.

3.5 Vacation. During each year of the Term, the Executive shall be entitled to a vacation period or periods in accordance with the vacation policy of the Company as in effect from time to time, but not less than the Executive’s current entitlement of four weeks. 

3.6 Fringe Benefits. 

(i) During the Term, the Executive shall be entitled to continue to participate in those qualified and non-qualified defined benefit, defined contribution, insurance, medical (including the Revlon Executive Supplemental Medical Plan), dental, disability and other benefit plans and programs of the Company as from time to time in effect (or their successors) in which the Executive participated on the date hereof and in such other plans and programs and in such perquisites as may be made available to senior executives of the Company of the Executive’s level generally. In addition, during the Term the Company shall provide to the Executive an automobile of a class appropriate to the Executive’s grade from time to time (but in any event equivalent to the automobile provided on the date of this Agreement), including all operating costs thereof, insurance, maintenance and
parking, and the Executive shall be entitled to reimbursement for tax preparation and financial counseling services and health club membership with annual maximums at least comparable to those in effect on the date of this Agreement.

(ii) During the Term, RCPC shall provide Executive, at no cost to Executive, with additional life insurance (in excess of the basic life insurance of two times Executive’s Base Salary provided to employees at no cost) of two times Executive’s Base Salary. Notwithstanding any limitations in the qualified and/or non-qualified defined benefit pension plans, Executive shall be entitled to receive a defined pension benefit at age 62 as if Executive had elected to receive his pension benefit at age 65 (that is without reduction by reason of electing to receive benefits at age 62).

4. Termination.

 

 

4.1 Death. If the Executive shall die during the Term, the Term shall terminate and no further amounts or benefits shall be payable hereunder except pursuant to life insurance and qualified and non-qualified pension benefits provided under Section 3.6. 

4.2 Disability. If during the Term the Executive shall become physically or mentally disabled, whether totally or partially, such that the Executive is unable to perform the Executive’s services hereunder for (i) a period of six consecutive months or (ii) shorter periods aggregating six months during any twelve month period, RCPC may at any time after the last day of the six consecutive months of disability or the day on which the shorter periods of disability shall have equaled an aggregate of six months, by written notice to the Executive (but before the Executive has returned to active service following such disability), terminate the Term and no further amounts or benefits shall be payable hereunder except as provided in Section 3.6 and except that the Executive shall be entitled to receive until
the first to occur of (x) the Executive ceasing to be disabled or (y) the Executive attaining age 65, continued coverage for the Executive under the life insurance provided under Section 3.6 and continued medical and dental coverage (including the executive medical plan) for the Executive and his immediate family to the extent permitted by such plans and to the extent such benefits are provided to the Company’s actively employed senior executive generally.

 

 

 

 

 

-3-

 

4.3 Cause. RCPC may at any time by written notice to the Executive terminate the Term for “Cause” and, upon such termination, the Executive shall be entitled to receive no further amounts or benefits hereunder, except for accrued, but unpaid, salary as of such date and as required by law. As used herein the term “Cause” shall mean gross neglect by the Executive of the Executive’s duties hereunder, conviction of the Executive of any felony, conviction of the Executive of any lesser crime or offense involving the property of the Company or any of its affiliates, willful misconduct by the Executive in connection with the performance of the Executive’s duties hereunder or other material breach by the Executive of this Agreement or any breach of the Revlon Code of Business Conduct
or the Employee Agreement as to Confidentiality and Non-Competition. 

4.4 Company Breach; Other Termination. The Executive shall be entitled to terminate the Term and the Executive’s employment upon 60 days’ prior written notice in the event that (i) RCPC materially breaches any of its obligations hereunder, (ii) a material adverse change in the position, title or reporting structure of the Executive, or (iii) a relocation of Revlon, Inc.’s headquarters outside the New York metropolitan area or the relocation of the Executive’s principal place of employment to any location other than such headquarters, provided the Company shall fail to cure any such event described in (i), (ii) or (iii) within 30 days after such notice; or that at any time prior to a Change of Control, the Compensation Committee (or other appropriate Committee) of the Board of Directors
of Revlon, Inc. shall fail to grant awards pursuant to Section 3.3. In addition, RCPC shall be entitled to terminate the Term and the Executive’s employment at any time and without prior notice otherwise than pursuant to the provisions of Section 4.3. In consideration of the Executive’s covenant in Section 5.2, upon termination under this Section 4.4 by the Executive, or in the event RCPC so terminates the Term pursuant to this Section 4.4, RCPC agrees, and the Company’s sole obligation arising from such termination (except as otherwise provided in Section 3.6) shall be (at the Executive’s election by written notice within 10 days after such termination), for RCPC either

(i) to make the payment in lieu of bonus prescribed by Section 3.2 and to continue payments in lieu of Base Salary in the amounts prescribed by Section 3.1 and continue the Executive’s participation in the group life insurance and in the medical, dental and other perquisites of the Company in which the Executive was entitled to participate pursuant to Section 3.6 (in each case less amounts required by law to be withheld) through the date on which the Term would have expired pursuant to Section 2.2, if RCPC had given notice of non-extension of the Term on or as promptly as permitted by Section 2.2 after the date of termination of employment, provided that such benefit continuation is subject to the terms of such plans, provided further that such group life insurance continuation is subject to a limit of two years pursuant to the terms thereof, provided further that the Executive
shall cease to be covered by medical and/or dental plans of the Company at such time as the Executive becomes covered by like plans of another company, and provided finally that the Executive shall, as a condition, execute such release, confidentiality, non-competition and other covenants as would be required in order for the Executive to receive payments and benefits under the Policy referred to in clause (ii) below, or 

(ii) to make the payments and provide the benefits prescribed by the Executive Severance Policy upon the Executive’s compliance with the terms thereof, provided that in no event shall the severance period be less than 24 months. 

Any compensation earned by the Executive from other employment or a consultancy shall reduce the payments required pursuant to clause (i) above or shall be governed by the terms of the Executive Severance Policy as modified by the foregoing in the case of clause (ii) above.

4.5 Litigation Expenses. If RCPC and the Executive become involved in any action, suit or proceeding relating to the alleged breach of this Agreement by RCPC or the Executive, then if and to the extent that a final judgment in such action, suit or proceeding is rendered in favor of the Executive, RCPC shall reimburse the Executive for all expenses (including reasonable attorneys’ fees) incurred by the Executive in connection with such action, suit or proceeding or the portion thereof adjudicated in favor of the Executive. Such costs shall be paid to the Executive promptly upon presentation of expense statements or other supporting information evidencing the incurrence of such expenses. 

4.6
  Internal Revenue Code Section 409A.
  Section 409A (“Section 409A”) of the Internal Revenue Code of 1986,
  as amended, and/or its related rules and regulations, imposes additional taxes
  and interest on compensation or benefits deferred under certain nonqualified
  deferred compensation plans (as defined under the Code and related regulations).
  These plans may include, among others, nonqualified retirement plans, bonus
  plans, stock option plans, employment agreements and severance agreements. If
  any provision of this Agreement does not satisfy the requirements of Section
  409A, such provision shall be applied in a manner consistent with those requirements,
  notwithstanding any provision of the Agreement. If any provision of the Agreement
  would subject Executive to additional tax or interest under Section 409A, RCPC
  shall reform the provision. However, the Company shall maintain to the maximum
  extent practicable the original intent of the applicable provision without subjecting
  Executive to additional tax or interest, and the Company shall not be required
  to incur any additional compensation expense as a result of the reformed provision.

5. Protection of Confidential Information; Non-Competition.

5.1 The Executive acknowledges that the Executive’s services will be unique, that they will involve the development of Company-subsidized relationships with key customers, suppliers, and service providers as well as with key Company employees and that the Executive’s work for the Company has given and will give the Executive access to highly confidential information not available to the public or competitors, including trade secrets and confidential marketing, sales, product development and other data and plans which it would be impracticable for the Company to effectively protect and preserve in the absence of this Section 5 and the disclosure or misappropriation of which could materially adversely affect the Company. Accordingly, the

 

 

 

 

 

 

-4-

 

Executive agrees:

5.1.1 except in the course of performing the Executive’s duties provided for in Section 1.1, not at any time, whether during or after the Executive’s employment with the Company, to divulge to any other entity or person any confidential information acquired by the Executive concerning the Company’s or its affiliates’ financial affairs or business processes or methods or their research, development or marketing programs or plans, any other of its or their trade secrets, any information regarding personal matters of any directors, officers, employees or agents of the Company or its affiliates or their respective family members, or any information concerning the circumstances of the Executive’s employment and any termination of the Executive’s employment with the Company or any information regarding discussions related to any of the foregoing. The
foregoing prohibitions shall include, without limitation, directly or indirectly publishing (or causing, participating in, assisting or providing any statement, opinion or information in connection with the publication of) any diary, memoir, letter, story, photograph, interview, article, essay, account or description (whether fictionalized or not) concerning any of the foregoing, publication being deemed to include any presentation or reproduction of any written, verbal or visual material in any communication medium, including any book, magazine, newspaper, theatrical production or movie, or television or radio programming or commercial or over the internet. In the event that the Executive is requested or required to make disclosure of information subject to this Section 5.1.1 under any court order, subpoena or other judicial process, the Executive will promptly notify RCPC, take all reasonable steps requested by RCPC to defend against the compulsory disclosure and permit RCPC to
control with counsel of its choice any proceeding relating to the compulsory disclosure. The Executive acknowledges that all information the disclosure of which is prohibited by this section is of a confidential and proprietary character and of great value to the Company.

5.1.2 to deliver promptly to the Company on termination of the Executive’s employment with the Company, or at any time that RCPC may so request, all memoranda, notes, records, reports, manuals, drawings, blueprints and other documents (and all copies thereof) relating to the Company’s business and all property associated therewith, which the Executive may then possess or have under the Executive’s control, including, without limitation, computer disks or data (including data retained on any computer), and any home office equipment or computers purchased or provided by Revlon or other materials.

5.2 In consideration of RCPC’s covenant in Section 4.4, the Executive agrees (i) in all respects fully to comply with the terms of the Employee Agreement as to Confidentiality and Non-Competition (the “Non-Competition Agreement”), whether or not the Executive is a signatory thereof, with the same effect as if the same were set forth herein in full, and (ii) in the event that the Executive shall terminate the Executive’s employment otherwise than as provided in Section 4.4, the Executive shall comply with the restrictions set forth in paragraph 9(e) of the Non-Competition Agreement through the earliest date on which the Term would have expired pursuant to Section 2.2 if RCPC had given notice of non-extension of the Term on the date of termination of employment, subject only to the Company continuing to make payments equal to the Executive’s Base Salary during
such period, notwithstanding the limitation otherwise applicable under paragraph 9(d) thereof or any other provision of the Non-Competition Agreement. 

5.3 If the Executive commits a breach of any of the provisions of Sections 5.1 or 5.2 hereof, RCPC shall have the following rights and remedies:

5.3.1 the right and remedy to immediately terminate all further payments and benefits provided for in this Agreement, except as may otherwise be required by law in the case of qualified benefit plans,

5.3.2 the right and remedy to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach will cause irreparable injury to the Company and that money damages and disgorgement of profits will not provide an adequate remedy to the Company, and, if the Executive attempts or threatens to commit a breach of any of the provisions of Sections 5.1 or 5.2, the right and remedy to be granted a preliminary and permanent injunction in any court having equity jurisdiction against the Executive committing the attempted or threatened breach (it being agreed that each of the rights and remedies enumerated above shall be independent of the others and shall be severally enforceable, and that all of such rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available
to RCPC under law or in equity), and

5.3.3
  the right and remedy to require the Executive to account for and pay over to
  the Company all compensation, profits, monies, accruals, increments or other
  benefits (collectively “Benefits”) derived or received by the Executive
  as the result of any transactions constituting a breach of any of the provisions
  of Sections 5.1 or 5.2 hereof, and the Executive hereby agrees to account for
  and pay over such Benefits as directed by RCPC. 

5.4 If any of the covenants contained in Sections 5.1, 5.2 or 5.3, or any part thereof, hereafter are construed to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect, without regard to the invalid portions.

5.5 If any of the covenants contained in Sections 5.1 or 5.2, or any part thereof, are held to be unenforceable because of the duration of such provision or the area covered thereby, the parties agree that the court making such determination shall have the power to reduce the duration and/or area of such provision so as to be enforceable to the maximum extent permitted by applicable law and, in its reduced form, said provision shall then be enforceable.

5.6 The parties hereto intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 5.1, 5.2 and 5.3 upon the courts of any state within the geographical scope of such covenants. In the event that the courts of any one or more of such states shall hold such covenants wholly unenforceable by reason of the breadth of such covenants or otherwise, it is the 

 

 

 

 

 

 

-5-

 

intention of the parties hereto that such determination not bar or in any way affect RCPC’s right to the relief provided above in the courts of any other states within the geographical scope of such covenants as to breaches of such covenants in such other respective jurisdictions, the above covenants as they relate to each state being for this purpose severable into diverse and independent covenants.

5.7 Any termination of the Term or the Executive’s employment shall have no effect on the continuing operation of this Section 5.

6. Inventions and Patents.

6.1 The Executive agrees that all processes, technologies and inventions (collectively, “Inventions”), including new contributions, improvements, ideas and discoveries, whether patentable or not, conceived, developed, invented or made by him during the Term shall belong to the Company, provided that such Inventions grew out of the Executive’s work with the Company or any of its subsidiaries or affiliates, are related in any manner to the business (commercial or experimental) of the Company or any of its subsidiaries or affiliates or are conceived or made on the Company’s time or with the use of the Company’s facilities or materials. The Executive shall further: (a) promptly disclose such Inventions to the Company; (b) assign to the Company, without additional compensation, all patent and other rights to such Inventions for the United States and foreign
countries; (c) sign all papers necessary to carry out the foregoing; and (d) give testimony in support of the Executive’s inventorship.

6.2 If any Invention is described in a patent application or is disclosed to third parties, directly or indirectly, by the Executive within two years after the termination of the Executive’s employment with the Company, it is to be presumed that the Invention was conceived or made during the Term.

6.3 The Executive agrees that the Executive will not assert any rights to any Invention as having been made or acquired by the Executive prior to the date of this Agreement, except for Inventions, if any, disclosed to the Company in writing prior to the date hereof.

7. Intellectual Property.

Notwithstanding and without limitation of Section 6, the Company shall be the sole owner of all the products and proceeds of the Executive’s services hereunder, including, but not limited to, all materials, ideas, concepts, formats, suggestions, developments, arrangements, packages, programs and other intellectual properties that the Executive may acquire, obtain, develop or create in connection with or during the Term, free and clear of any claims by the Executive (or anyone claiming under the Executive) of any kind or character whatsoever (other than the Executive’s right to receive payments hereunder). The Executive shall, at the request of RCPC, execute such assignments, certificates or other instruments as RCPC may from time to time deem necessary or desirable to evidence, establish, maintain, perfect, protect, enforce or defend its right, title or interest in or to
any such properties.

8. Revlon Code of Business Conduct.

In consideration of the Company’s execution of this Agreement, the Executive agrees in all respects to fully comply with the terms of the Revlon Code of Business Conduct, annexed at Schedule A, whether or not the Executive is a signatory thereof, with the same effect as if the same were set forth herein in full.

9. Indemnification.

Subject to the terms, conditions and limitations of its by-laws and applicable Delaware law, RCPC will defend and indemnify the Executive to the fullest extent permissible under its by-laws and applicable law against all costs, charges and expenses, including, without limitation, the advancement of legal fees and expenses to, or on behalf of, the Executive, incurred or sustained by the Executive in connection with any action, suit or proceeding to which the Executive may be made a party, brought by any shareholder of the Company directly or derivatively or by any third party by reason of any act or omission of the Executive as an officer, director or employee of the Company or of any subsidiary or affiliate of the Company. In addition, at all times during the Term and for any claims asserted after the Term, the Executive shall be covered by Revlon, Inc.’s and RCPC’s directors and
officer’s liability insurance policy to the same extent as the other senior most executives and directors of Revlon, Inc. and RCPC.

10. Notices.

All notices, requests, consents and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given if delivered personally, sent by overnight courier or mailed first class, postage prepaid, by registered or certified mail (notices mailed shall be deemed to have been given on the date mailed), as follows (or to such other address as either party shall designate by notice in writing to the other in accordance herewith):

If to the Company, to:

Revlon Consumer Products Corporation

237 Park Avenue

New York, New York 10017

Attention: President and Chief Executive Officer

 

 

 

 

 

 

-6-

 

If to the Executive, to the Executive’s principal residence as reflected in the records of the Company.

11. General.

11.1 This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York applicable to agreements made between residents thereof and to be performed entirely in New York.

11.2 The section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

11.3 This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof. No representation, promise or inducement has been made by either party that is not embodied in this Agreement, and neither party shall be bound by or liable for any alleged representation, promise or inducement not so set forth.

11.4 This Agreement, and the Executive’s rights and obligations hereunder, may not be assigned by the Executive, nor may the Executive pledge, encumber or anticipate any payments or benefits due hereunder, by operation of law or otherwise. RCPC may assign its rights, together with its obligations, hereunder (i) to any affiliate or (ii) to a third party in connection with any sale, transfer or other disposition of all or substantially all of any business to which the Executive’s services are then principally devoted, provided that no assignment pursuant to clause (ii) shall relieve RCPC from its obligations hereunder to the extent the same are not timely discharged by such assignee.

11.5 This Agreement may be amended, modified, superseded, canceled, renewed or extended and the terms or covenants hereof may be waived, only by a written instrument executed by both of the parties hereto, or in the case of a waiver, by the party waiving compliance. The failure of either party at any time or times to require performance of any provision hereof shall in no manner affect the right at a later time to enforce the same. No waiver by either party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this Agreement.

11.6 This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.

12. Subsidiaries and Affiliates. As used herein, the term “subsidiary” shall mean any corporation or other business entity controlled directly or indirectly by the corporation or other business entity in question, and the term “affiliate” shall mean and include any corporation or other business entity directly or indirectly controlling, controlled by or under common control with the corporation or other business entity in question.

13. Change of Control.

13.1 Change of Control Payments and Benefits. 

(a) Extension of Term. In the event of any Change of Control, as defined on Schedule B, the Term of the Executive’s Agreement shall be automatically extended for 24 months from the effective date (the “COC Effective Date”) of any such Change of Control (the “Extended Term”). 

(b) Benefit Continuation; Bonus and Salary Payment. If during the Extended Term, the Executive terminates the Term of his employment for “COC Good Reason” (as defined below in subclause (b)(iii)) or if the Company terminates the Term of the Executive’s employment other than for “Cause” (as defined in Section 4.3 of the Agreement):

(i)
  the Company shall provide for a period of two years from such termination date
  all fringe benefits then provided to the Executive, including, without limitation,
  qualified and non-qualified defined benefit, defined contribution, insurance,
  medical (including the Revlon Executive Supplemental Medical Plan), dental,
  disability, automobile, financial planning, tax preparation and other benefit
  plans and programs of the Company as from time to time in effect (or their successors)
  in which the Executive participated on the COC Effective Date or in lieu of
  providing such benefits the Company shall make a cash payment to the Executive
  equal to the value of such benefits.

(ii) the Company shall immediately pay to the Executive in a cash lump sum payment two times the sum of (A) the greater of the Executive’s base salary in effect on (1) the COC Effective Date or (2) such termination date plus (B) the average amount of the gross bonus amounts earned by the Executive over the five calendar years preceding such termination. 

(iii) “COC Good Reason” means, for purposes of this subclause (b) only (and not for any other purpose or reason under this Agreement): (A) a material adverse change in the Executive’s job responsibilities; (B) any reduction in the Executive’s base salary; (C) any reduction in the Executive’s annual bonus opportunity; (D) any reduction in the 

 

 

 

 

 

 

-7-

 

Executive’s aggregate value of benefits; or (E) the Executive’s being required by the Company to relocate beyond a 50 mile radius of the Executive’s then current residence.

(iv) The Executive shall have no duty to mitigate by seeking other employment or otherwise and no compensation earned by the Executive from other employment, a consultancy or otherwise shall reduce any payments provided for under this Agreement.

(c) Equity Compensation. In the event of any Change of Control, all then unvested stock options and restricted shares held by the Executive shall immediately vest and be fully exercisable and all restrictions shall lapse.

(d) Governing Provision. In the event of any conflict between this Section 13 of the Agreement and any other section or provision of the Agreement, the section which provides the Executive with most favored treatment in the event of a Change of Control shall govern and prevail.

13.2 Section 280G.

(a) If the aggregate of all amounts and benefits due to the Executive under this Agreement or any other plan, program, agreement or arrangement of the Company or any of its Affiliates, which, if received by the Executive in full, would constitute “parachute payments” as such term is defined in and under Section 280G of the Code (collectively, “Change of Control Benefits”), reduced by all Federal, state and local taxes applicable thereto, including the excise tax imposed pursuant to Section 4999 of the Code, is less than the amount the Executive would receive, after all such applicable taxes, if the Executive received aggregate Change of Control Benefits equal to an amount which is $1.00 less than three times the Executive’s “base amount”, as defined in and determined under Section 280G of the Code, then such Change of Control Benefits shall be
reduced or eliminated to the extent necessary so that the Change of Control Benefits received by the Executive will not constitute parachute payments. If a reduction in the Change of Control Benefits is necessary, reduction shall occur in the following order unless the Executive elects in writing a different order, subject to the Company’s consent (which consent shall not be unreasonably withheld): first, a reduction of cash payments not attributable to equity awards which vest on an accelerated basis; second, the cancellation of accelerated vesting of stock awards; third, the reduction of employee benefits; and fourth, a reduction in any other “parachute payments”. If acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of the Executive’s stock awards unless the Executive elects in writing a different order for cancellation.

(b) It is possible that after the determinations and selections made pursuant to Section 13.2(a) above the Executive will receive Change of Control Benefits that are, in the aggregate, either more or less than the amounts contemplated by Section 13.2(a) above (hereafter referred to as an “Excess Payment” or “Underpayment”, respectively). If there is an Excess Payment, the Executive shall promptly repay the Company an amount consistent with this Section 13.2. If there is an Underpayment, the Company shall pay the Executive an amount consistent with this Section 13.2.

(c) The determinations with respect to this Section 13.2 shall be made by an independent auditor (the “Auditor”) compensated by the Company. The Auditor shall be the Company’s regular independent auditor, unless the Executive objects to the use of that firm, in which event the Auditor shall be a nationally-recognized United States public accounting firm chosen by the Company and approved by the Executive (which approval shall not be unreasonably withheld or delayed). For purposes of this Agreement, the term “Code” shall mean the Internal Revenue Code of 1986, as amended, including all final regulations promulgated thereunder and any reference to a particular section of the Code shall include any provision that modifies, replaces or supersedes such section. 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

 

  	
                         
 	
                        REVLON CONSUMER PRODUCTS CORPORATION
 
	
                          
 	
                         
 	
        By:
 	
                        
 /s/ David L. Kennedy
 
	
                         
 	
                         
 	
                        David Kennedy
 
	
                         
 	
                         
 	
                        President and Chief Executive Officer
 

 

 

  	
         

      	
                         
 	
         
 	
                         
 
	
                          
 	
                         
 	
                         
 	
                        
 /s/ Robert K. Kretzman
 
	
                         
 	
                         
 	
                         
 	
                        Robert K. Kretzman, the Executive
 

 

 

 

 

 

 

-8-

 

SCHEDULE A

REVLON CODE OF BUSINESS CONDUCT

 

 

 

 

 

-9-

 

SCHEDULE B

A “Change of Control” shall be deemed to have occurred if the event set forth in any one of the following paragraphs shall have occurred:

(i) any Person, other than one or more Permitted Holders, is or becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 under the Exchange Act, except that for purposes of this definition a Person will be deemed to have “beneficial ownership” of all shares that any such Person has the right to acquire, whether such right is exercisable immediately or only after the passage of time), directly or indirectly, of more than 50% of the total voting power of the Voting Stock of the Company; provided that under such circumstances the Permitted Holders do not have the right or ability by voting power, contract or otherwise to elect or designate for election a majority of the Board of Directors of the Company (for the purposes of this clause (i) and clause (iii), such other Person will be deemed to beneficially own any Voting Stock of a specified corporation held by a
parent corporation, if such other Person beneficially owns, directly or indirectly, more than 50% of the voting power of the Voting Stock of such parent corporation and the Permitted Holders do not have the right or ability by voting power, contract or otherwise to elect or designate for election a majority of the Board of Directors of such parent corporation);

(ii) during any period of two consecutive years, individuals who at the beginning of such period constituted the Board of Directors of the Company (together with any new directors whose election by such Board of Directors or whose nomination for election by the shareholders of the Company was approved by a vote of 66-2/3% of the directors of the Company then still in office who were either directors at the beginning of such period or whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the Board of Directors of the Company then in office; 

(iii) the shareholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets to an entity in which any Person, other than one or more Permitted Holders is or becomes the Beneficial Owner (as defined in Rules 13d-3 and 13d-5 under the Exchange Act, except that for purposes of this definition a Person will be deemed to have “beneficial ownership” of all shares that any Person has the right to acquire, whether such right is exercisable immediately or only after the passage of time), directly or indirectly, of securities of such entity representing 50% or more of the combined voting power of such entity’s Voting Stock, and the Permitted Holders “beneficially own” (as so defined) directly or
indirectly, in the aggregate a lesser percentage of the total voting power of the Voting Stock of such entity than such other Person and do not have the right or ability by voting power, contract or otherwise to elect or designate for election a majority of the Board of Directors of such entity; or

(iv) a “Change of Control” shall have occurred under, and as defined in, the indenture governing Revlon Consumer Products Corporation’s 8 5/8% Senior Subordinated Notes Due 2008 or any other Subordinated Obligations of Revlon Consumer Products Corporation so long as such 8 5/8% Senior Subordinated Notes Due 2008 or Subordinated Obligations are outstanding. 

Notwithstanding the foregoing, a “Change of Control” shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders of the common stock of the Company immediately prior to such transaction or series of transactions continue to have substantially the same combined voting power of the Voting Stock in an entity which owns all or substantially all of the assets of the Company immediately following such transaction or series of transactions.

“Capital Stock” of any Person shall mean any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) equity of such Person, including any Preferred Stock, but excluding any debt securities convertible into or exchangeable for such equity. 

“Company” means Revlon, Inc. together with its subsidiaries, including, without limitation, Revlon Consumer Products Corporation.

“8 5/8% Senior Subordinated Notes Due 2008” means Revlon Consumer Products Corporation’s 8 5/8% Senior Subordinated Notes due 2008 and any notes exchanged therefor.

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time. 

“Permitted Holders” means Ronald O. Perelman (or in the event of his incompetence or death, his estate, heirs, executor, administrator, committee or other personal representative (collectively, “heirs”)) or any Person controlled, directly or indirectly, by Ronald O. Perelman or his heirs.

“Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

-10-

 

“Preferred Stock,” as applied to the Capital Stock of the Company, means Capital Stock of any class or classes (however designated) which is preferred as to the payment of dividends, or as to the distribution of assets upon any voluntary or involuntary liquidation or dissolution of the Company, over shares of Capital Stock of any other class of the Company. 

“Subordinated Obligations” has the meaning ascribed thereto in the indenture for Revlon Consumer Products Corporation’s 91⁄2% Senior Notes due 2011.

“Voting Stock” means all classes of Capital Stock of the Company then outstanding and normally entitled to vote in the election of Directors.1
	 

	 
		

	 

	 
		Confidential Treatment has been requested for portions
		of this exhibit. The copy filed herewith omits the information subject to the
		confidentiality request.  Omissions are designated as “*”. A
		complete version of this exhibit has been filed separately with the Securities
		and Exchange Commission
	 

	 
		

	 

	 
		(1)
	 

	 
		GENTA INCORPORATED
	 

	 
		

	 

	 
		(2)
	 

	 
		IDIS LIMITED
	 

	 
		

	 

	 
		

	 

	 
		

	 

	 
		

	 

	 

	 
		

	 

	 
		SUPPLY AND DISTRIBUTION AGREEMENT
	 

	 
		

	 

	 
		

	 

	 
		

	 

	 
	 

	 

	 
		
 

	 

	 
		1
	 

	 
		

	 

	 
	 
		

	 

	 
		DATE
	 

	 
		March 6, 2007
	 

	 
		

	 

	 
		PARTIES
	 

	 
		

	 

	 
		(1)
	 

	 
		 GENTA INCORPORATED, a company incorporated in the State of
		Delaware, United States of America, whose registered office is at 200 Connell
		Drive, Berkeley Heights, NJ  07922 USA
	 

	 
		

	 

	 
		(“GENTA”)
	 

	 
		

	 

	 
		(2)
	 

	 
		IDIS LIMITED, a company incorporated in England (registered number
		2143039), whose registered office is at IDIS House, Churchfield Road,
		Weybridge, Surrey, KT13 8DB, United Kingdom
	 

	 
		

	 

	 
		(“IDIS")  
	 

	 
		

	 

	 
		

	 

	 
		INTRODUCTION 
	 

	 
		

	 

	 
		A)
	 

	 
		GENTA wishes to supply the Products in the Territory through an entity
		with experience in the distribution of unlicensed products on a Named Patient
		Supply basis.
	 

	 
		

	 

	 
		B)
	 

	 
		IDIS has capability in the distribution of unlicensed products on a Named
		Patient Supply basis, within each country in the Territory and wishes to
		act as GENTA’s distributor of the Products in the Territory.
	 

	 
		

	 

	 
		C)
	 

	 
		GENTA appoints IDIS as its Exclusive distributor of the Products in the
		Territory on a Named Patient Supply basis on the terms set out in this
		Agreement.
	 

	 
		

	 

	 
		

	 

	 
		OPERATIVE PROVISIONS
	 

	 
		

	 

	 
		1.
	 

	 
		Definitions and interpretation 
	 

	 
		In this Agreement the following words have the following meanings:
	 

	 
		“Business Day” means any day other than a Saturday or Sunday or
		a public or bank holiday in England or USA;
	 

	 
		“Commencement Date” means the date of signature of this
		Agreement by both parties;
	 

	 
		“Confidential Agreements” means any and all confidential
		agreements entered into between the parties either before or after the
		Commencement Date relating to the subject matter of this Agreement;
		“Confidential Information” means all information which is
		commercially sensitive or of a secret nature, or information which is marked
		confidential, or which is orally stated to be confidential and confirmed in
		writing as confidential within thirty (30) days thereafter, relating to any and
		all aspects of the business of either party, including any confidential
		information set out in Confidentiality Agreements;
	 

	 
		“Contract” has the meaning set out in clause 7.2;
	 

	 
		“Exclusive” means a right granted under this Agreement which
		GENTA will not itself exercise and will not authorise any other person to
		exercise;
	 

	 
		

	 

	 
		2
	 

	 
		

	 

	 
	 
		

	 

	 
		“Fax Address” means the fax address of the relevant party given
		in Schedule 4;
	 

	 
		“Field” means the distribution of unlicensed products on a
		Named Patient Supply basis.
	 

	 
		“FOC Product” means Product distributed by IDIS to the customer
		without charge except for shipping costs, in accordance with clause 5.
		 
	 

	 
		“Force Majeure” means any circumstances beyond the reasonable
		control of the relevant party (including, without limitation, any strike,
		lock-out or other form of industrial action, acts of God, war or national
		emergency, an act of terrorism, riot, civil commotion, malicious damage,
		compliance with any law or government order, rule, regulation or direction,
		accident, fire, flood or storm) which prevents that party from complying with
		any or all of its obligations under this Agreement;
	 

	 
		“Indication” means the symptoms, condition, or disease for
		which the Product has been prescribed for a particular Named Patient;
	 

	 
		

	 

	 
		“Intellectual Property Rights” means all intellectual and
		industrial property rights including patents, know-how, registered trade marks,
		registered designs, utility models, applications for and rights to apply for
		any of the foregoing, unregistered design rights, unregistered trade marks,
		rights to prevent passing off for unfair competition and copyright, database
		rights, topography rights and any other rights in any invention, discovery or
		process, in each case in the United Kingdom and all other countries in the
		world and together with all renewals and extensions;
	 

	 
		“Marketing Authorisation” means an authorisation for the sale
		and placing on the market or marketing of a Product within the Territory;
	 

	 
		“Named Patient” means the patient for whom the Product(s) have
		been prescribed;
	 

	 
		“Named Patient Supply” means the supply of Products which do
		not have a Marketing Authorisation for the indication in the country of
		destination and are supplied to meet the special needs of a specific patient or
		patients under the order of a medical practitioner or other person lawfully
		permitted to prescribe such Products to a specific patient or patients in the
		Territory or relevant part of it in accordance with all laws and regulatory
		requirements as they apply to such supply;
	 

	 
		“Orders” has the meaning set out in clause 7.1;
	 

	 
		"Prices" means the IDIS Buy Price, net of the IDIS Fee/Pack, to be paid
		by IDIS to GENTA for the Products as set out in Schedule 1 of this
		Agreement, or as varied in accordance with clause 6.1;
	 

	 
		"Products" means the product or products listed in Schedule 1 and
		additionally any further products of GENTA offered to be supplied to IDIS by
		GENTA in writing from to time to time after the Commencement Date and accepted
		in writing by IDIS;
	 

	 
		"Service Address" means the address for service of the relevant party
		given in Schedule 4 of this Agreement;
	 

	 
		

	 

	 
		3
	 

	 
		

	 

	 
	 
		

	 

	 
		“Technical Agreement” means the Technical Agreement for
		Distribution Services separately executed by the parties in connection with
		this Agreement;
	 

	 
		“Term” means a period of  * years.
	 

	 
		"Territory" means those countries set out in Schedule 2 of this
		Agreement and additionally any further countries agreed between the parties in
		writing from time to time after the Commencement Date;
	 

	 
		"Trade Marks" means the trade marks and trade names of GENTA listed in
		Schedule 3 and such other trade marks as GENTA notifies to IDIS in
		writing from time to time after the Commencement Date;
	 

	 
		"Year" means the period of 12 months beginning on the Commencement Date
		and each subsequent period of 12 months commencing on the anniversary of the
		Commencement Date during the continuance of this Agreement.
	 

	 
		1.1.
	 

	 
		Headings to the clauses of and Schedules to this Agreement are for
		convenience only and shall not affect its construction or interpretation.
	 

	 
		1.2.
	 

	 
		References to clauses and Schedules are to the clauses of and Schedules
		of this Agreement.
	 

	 
		1.3.
	 

	 
		The Schedules are deemed to be incorporated and form part of this
		Agreement and the term "Agreement" shall be construed accordingly.  In the
		event of conflict between any of the terms of this main part of the Agreement
		and the Schedules, the former shall prevail.
	 

	 
		1.4.
	 

	 
		The word “indemnify” in this Agreement will mean to indemnify,
		keep indemnified and hold harmless the indemnified party from and against all
		third party costs (including the cost of enforcement), expenses, liabilities
		(including any tax liability), injuries, damages, claims, demands, proceedings
		or legal costs (on a full indemnity basis) and judgements which the indemnified
		party incurs or suffers and “indemnity”, “indemnities” and
		“indemnifies” have a corresponding meaning.
	 

	 
		1.5.
	 

	 
		Any reference to a “month” is a reference to the period of a
		calendar month.
	 

	 
		1.6.
	 

	 
		Any reference to “person” means a natural or legal person, firm
		or unincorporated association.
	 

	 
		1.7.
	 

	 
		Words importing the singular include the plural and vice versa.
	 

	 
		2.
	 

	 
		Appointment and Restrictions
	 

	 
		2.1
	 

	 
		Subject to the terms and conditions of this Agreement, GENTA hereby
		grants to IDIS the Exclusive right within the Field to distribute on its own
		account the Products in the Territory and IDIS agrees to act in this capacity
		subject to the terms of this Agreement.
	 

	 
		2.2
	 

	 
		During the continuance of this Agreement, GENTA undertakes not to market
		or sell the Products within the Field directly or indirectly to any other
		person in the Territory without first obtaining IDIS’s express written
		consent (such consent not to be unreasonably withheld or delayed).
	 

	 
		2.3
	 

	 
		During the continuance of this Agreement, IDIS undertakes not to seek
		customers or promote sales of the Products outside the Territory, and in any
		event shall not sell or distribute any Product within the United States.
	 

	 
		

	 

	 
		4
	 

	 
		

	 

	 
	 
		

	 

	 
		2.4
	 

	 
		IDIS undertakes that it shall not unless otherwise approved in writing by
		GENTA during the continuance of this Agreement:
	 

	 
		2.4.1
	 

	 
		Knowingly manufacture, sell or distribute any goods that compete with the
		Products in the Territory;
	 

	 
		2.4.2
	 

	 
		obtain its supplies of the Products for distribution within the Territory
		other than from GENTA; provided that GENTA is able and willing to supply the
		same on the terms of this Agreement.
	 

	 
		2.5
	 

	 
		IDIS undertakes that while the currently pending MAA for GENASENSE is
		pending and under review by the EMEA, with respect to GENASENSE in any EU
		member state it shall not:
	 

	 
		

	 

	 
		2.5.1
	 

	 
		commence any regulatory action;
	 

	 
		 
	 

	 
		2.5.2
	 

	 
		communicate with any regulatory authority;
	 

	 
		 
	 

	 
		2.5.3
	 

	 
		distribute or cause distribution either for sale or as FOC
		Product;
	 

	 
		

	 

	 
		without the express prior written consent of GENTA to any of the
		foregoing activities, which consent may be withheld in GENTA’s sole
		discretion.  In giving any such consent GENTA may, in its sole discretion,
		impose restrictions and/or limitations on the permitted activities, and IDIS
		shall comply in all respects with such restrictions and/or limitations.
	 

	 
		

	 

	 
		3.
	 

	 
		Term
	 

	 
		3.1
	 

	 
		This Agreement shall commence on the Commencement Date and subject to
		early termination in accordance with its terms shall continue in force in
		respect of each Product in each country of the Territory until *, at
		which time the Agreement shall terminate with respect to such Product in such
		country.
	 

	 
		3.2
	 

	 
		Following the Term, this Agreement shall be renewed automatically for
		additional, successive * periods unless and until this Agreement is
		earlier terminated as provided for herein or upon * days written notice
		by either party prior to the expiration of the then current Term, in which case
		this Agreement shall terminate at the end of the then-current Term.  
	 

	 
		4.
	 

	 
		Supply of the Products
	 

	 
		4.1.
	 

	 
		GENTA shall supply the Products to IDIS on a consignment basis in
		accordance with the terms and conditions of this Agreement to the exclusion of
		any terms and conditions of sale submitted at any time by either party and
		whether printed or sent with any order form, delivery note, invoice or
		otherwise.  GENTA shall be responsible for insuring the Products while in
		transit to IDIS. IDIS shall be responsible for adequately insuring the Products
		upon receipt thereof. For clarity, title or ownership of the Products shall not
		pass to IDIS but shall pass directly to the consumer. IDIS shall indicate to
		any third parties that its inventory of Product is owned by GENTA.
	 

	 
		4.2.
	 

	 
		GENTA shall not supply IDIS with any Products with a remaining shelf life
		of less than * months, and GENTA shall replace any Product supplied to
		IDIS that expires prior to distribution.  IDIS will have no obligation to
		pay the IDIS Buy Price for any such expired Product.  If GENTA is unable
		to comply with this clause 4.2 it shall notify IDIS immediately
		providing details of the remaining unexpired shelf lives of the available
		Products and, in such event, GENTA shall not proceed with the Order until it
		has received written confirmation from IDIS that the Order may proceed at which
		time the Contract shall be formed.
	 

	 
		

	 

	 
		5
	 

	 
		

	 

	 
	 
		

	 

	 
		5.
	 

	 
		Distribution of FOC Product  
	 

	 
		5.1
	 

	 
		GENTA or IDIS may, from time to time, receive requests from within the
		Territory for FOC Product.  Within 1-2 workings days of receipt of such
		request, IDIS shall forward the request to GENTA to the attention of its Drug
		Safety and Surveillance Department, including all information relevant to
		GENTA’s decision whether or not to approve the request.  IDIS shall
		not distribute Product to the requestor until such time as it has received
		written approval from GENTA, including any restrictions or limitations GENTA
		deems necessary or advisable.  
	 

	 
		

	 

	 
		5.2
	 

	 
		GENTA shall review any requests for FOC Product it receives directly and,
		if approved, shall advise IDIS in writing within 1-2 workings days that FOC
		Product is to be distributed to the requestor and including any restrictions or
		limitations GENTA deems necessary or advisable.  Any such written approval
		shall include any requestor contact information in GENTA’s possession.
		 
	 

	 
		

	 

	 
		5.3
	 

	 
		Approval for distribution of FOC Product is at GENTA’s sole
		discretion. Upon approval by GENTA, IDIS shall distribute FOC Product to the
		requestor according to the terms of this Agreement and in compliance with any
		restrictions or limitations imposed by GENTA.  IDIS shall include FOC
		Product distributions as a separate item in its monthly report to GENTA set
		forth in clause 10.2 below.
	 

	 
		

	 

	 
		6
	 

	 
		Pricing
	 

	 
		

	 

	 
		6.1
	 

	 
		IDIS shall pay GENTA the Prices for all distributed Product that is not
		FOC Product.  The IDIS Buy Price set forth in Schedule 1 shall remain
		fixed for the duration of the Agreement but may be varied by GENTA by giving
		IDIS not less than * days notice; save that nothing in this clause
		6.1 shall give GENTA the right to vary the IDIS Buy Price  in respect
		of Orders of Products placed by IDIS with GENTA prior to the date of receipt of
		any notice of price variation.   
	 

	 
		

	 

	 
		6.2
	 

	 
		GENTA shall pay IDIS the IDIS Fee/Pack set forth in Schedule 1 for all
		distributed Products including FOC product. The IDIS Buy Price will be waived
		For any FOC Product IDIS distributes proved IDIS has obtained GENTA’s
		approval for such distribution in accordance with clause 5.
	 

	 
		

	 

	 
		6.3
	 

	 
		All Prices are inclusive of packaging but exclusive of any applicable
		value added or any other sales tax for which IDIS shall be additionally liable.
		GENTA may recommend in writing to IDIS a sale price for each of the Products or
		impose a maximum selling price at any time; provided that that price does not
		amount to a minimum selling price or retail price maintenance.  For the
		avoidance of doubt:
	 

	 
		

	 

	 
		6.3.1
	 

	 
		where GENTA has recommended a selling price to IDIS, IDIS shall be free
		to distribute the Products at any price it so chooses; and
	 

	 
		6.3.2
	 

	 
		where GENTA has set a maximum price, IDIS shall be obliged to distribute
		the Products at no more than that price; provided that does not amount to a
		minimum selling price or retail price maintenance.  GENTA hereby sets a
		maximum price equal to the IDIS Buy Price, as it may be varied from time to
		time in accordance with clause 6.1.
	 

	 
		

	 

	 
		6
	 

	 
		

	 

	 
	 
		

	 

	 
		6.4
	 

	 
		In the event GENTA reduces the IDIS Buy Price to an amount below the IDIS
		Buy Price that is in effect on the Commencement Date, IDIS will continue to
		receive the IDIS Fee/Pack due as of the Commencement Date as set forth in
		Schedule 1.
	 

	 
		6.5
	 

	 
		In the event GENTA varies the IDIS Buy Price above the IDIS Buy Price
		that is in effect on the Commencement Date, the IDIS Fee/Pack will be adjusted
		in accordance with the %IDIS Fee/Pack as set forth in Schedule 1.
	 

	 
		6.6
	 

	 
		Without prejudice to any other provision of this Agreement, GENTA shall
		advise IDIS immediately if any Price given for Products in an Order is
		incorrect and, in such event where the Price is incorrect GENTA shall not
		proceed with the Order until it has notified IDIS of that fact and received
		written confirmation from IDIS that the Order may proceed, at which time the
		Contract shall be formed.
	 

	 
		7.
	 

	 
		Purchase Orders
	 

	 
		7.1
	 

	 
		IDIS shall submit, from time to time, written purchase orders
		(“Orders”) to GENTA for the supply of the Products.  Each
		Order shall stipulate the Products’ names, the Products’ codes, the
		quantity required and the total price of the Order (excluding VAT).
	 

	 
		7.2
	 

	 
		The receipt by IDIS of GENTA’s written confirmation that it will
		accept such of an Order during the term of this Agreement shall constitute a
		contract (“Contract”), subject to the terms and
		conditions of this Agreement.  
	 

	 
		7.3
	 

	 
		Notwithstanding clause 7.2 and 23.4, no less than * weeks
		prior to GENTA’s shipment date IDIS may vary, add or omit any or all of
		the Products in an Order by notice in writing to GENTA, provided if such change
		would have a material impact on GENTA’s ability to fulfill the order or
		cause GENTA to incur an additional cost, then IDIS shall first obtain
		GENTA’s prior approval, not to be unreasonably withheld or delayed.
		 Notwithstanding the foregoing, GENTA reserves the right to reject any
		Order variation or addition that it is unable fulfill and will be entitled to
		recover from IDIS any costs it incurs as a result of IDIS’ cancellation of
		an Order. GENTA shall not materially vary, add or omit any of the Products or
		any part of them from an Order without the express consent of IDIS. 
	 

	 
		7.4
	 

	 
		An update of all outstanding Orders placed by IDIS with GENTA shall be
		provided by GENTA as often as reasonably requested by IDIS but no more than
		once per week.  
	 

	 
		8.
	 

	 
		Delivery
	 

	 
		8.1
	 

	 
		Within five (5) Business Days of the receipt of an Order GENTA shall
		provide IDIS with an estimated date for delivery. GENTA will in any event give
		IDIS reasonable notice of the date of delivery.
	 

	 
		8.2
	 

	 
		GENTA shall use commercially reasonable endeavours to meet delivery dates
		and shall:
	 

	 
		8.2.1
	 

	 
		notify IDIS as soon as reasonably practicable of any anticipated or
		actual delays it experiences or anticipates experiencing in meeting an
		estimated delivery date;
	 

	 
		8.2.2
	 

	 
		provide IDIS with such details of the causes of such delays as IDIS
		reasonably requires; and
	 

	 
		

	 

	 
		7
	 

	 
		

	 

	 
	 
		

	 

	 
		8.2.3
	 

	 
		update IDIS at least once a week until the causes of such delays are
		rectified or lapse.
	 

	 
		8.3
	 

	 
		IDIS may, but is not obliged to, grant such extension of time as it
		considers in its sole opinion is appropriate for GENTA to deliver the Products
		on time without breaching the Contract or this Agreement.  Subject to the
		foregoing and without prejudice to any other rights or remedies available to
		IDIS, failure to meet the estimated delivery date or any subsequently agreed
		date within * days or notify IDIS of * shall entitle IDIS to
		terminate the Contract and/or the Agreement immediately.
	 

	 
		GENTA will not be liable for any failure or delay in providing the
		Products or for any failure to comply with its obligations under a Contract or
		this Agreement to the extent that such failure or delay is attributable to:
	 

	 
		

	 

	 
		any act or omission of IDIS, its employees, agents or subcontractors
		which affects GENTA's ability to provide the Products;
	 

	 
		

	 

	 
		the provision by IDIS of any inaccurate or incomplete data, information
		or documentation including without limitation in relation to any Order for the
		Products.
	 

	 
		

	 

	 
		8.4
	 

	 
		Unless otherwise agreed upon in writing, delivery of the Products shall
		take place at IDIS’ premises at Unit 22, Red Lion Road Business Park,
		Surbiton, Surrey KT6 7AQ (or such other premises within the United Kingdom as
		IDIS may notify to GENTA from time to time) and GENTA shall at its cost arrange
		for suitable transport to IDIS’ premises at Unit 22, Red Lion Road
		Business Park, Surbiton, Surrey KT6 7AQ (or such other premises within the
		United Kingdom as have been notified by IDIS to Genta) and arrange insurance
		therefore until the Products are received by IDIS.
	 

	 
		8.5
	 

	 
		Where the Products are to be delivered in instalments pursuant to this
		Agreement, without prejudice to clause 7.2, each instalment shall
		constitute a separate Contract and without prejudice to any other rights or
		remedies available to IDIS, failure by GENTA to deliver any one or more of the
		instalments within * days there from in accordance with the terms and
		conditions of the Agreement shall entitle IDIS to treat the Contract as a whole
		as repudiated and terminate the Contract as a whole immediately.
	 

	 
		8.6
	 

	 
		GENTA shall:
	 

	 
		8.6.1
	 

	 
		fax to IDIS at its Fax Address a copy of the delivery note for each
		delivery or instalment on the day of delivery and supply a copy of the delivery
		note with the delivered Products;
	 

	 
		8.6.2
	 

	 
		inform IDIS if an Order for Products exceeds 30kg by weight when
		providing IDIS with the estimated date for delivery under clause 8.1.
	 

	 
		8.7
	 

	 
		On delivery the Products shall be marked by IDIS in accordance with
		IDIS’s instructions and properly packed and secured so as to reach their
		destination in an undamaged condition in the ordinary course of events.
	 

	 
		9.
	 

	 
		Rejection
	 

	 
		9.1
	 

	 
		Notwithstanding any other provision of this Agreement, acceptance of
		Products shall not occur until IDIS or its agent or representative has been
		given two (2) business days to inspect the Products for compliance with the
		terms and conditions of this Agreement following delivery or, if later, within
		two (2) business days after any latent defect in any of the Products has become
		apparent; provided that latent defect has become apparent before the expiry of
		the warranty period set out in clause 14.1.  Any deficiencies shall
		be reported to GENTA within two (2) business days of discovery.
	 

	 
		

	 

	 
		8
	 

	 
		

	 

	 
	 
		

	 

	 
		9.2
	 

	 
		In the event of a breach of GENTA’s warranties in clauses
		14.1 or 14.2, or where IDIS becomes aware of a defect or latent
		defect pursuant to clause 9.1, IDIS may, within one (1) day of becoming
		aware of such breach or defect, reject such Products by notice to GENTA
		specifying the nature and quantity of the defective Products.  Within
		thirty (30) days of receipt of such notice GENTA, shall, collect the
		defective Products from IDIS at GENTA’s expense (including, without
		limitation, costs of carriage, insurance, export/import duties) or request that
		IDIS destroy the defective Products at GENTA’s expense including, without
		limitation, costs of carriage, insurance, export/import duties), and, for
		Products rejected for breach of the warranties in clause 14.1 or a
		defect or latent defect pursuant to clause 9.1:
	 

	 
		9.2.1
	 

	 
		where such Products have not yet been distributed by IDIS, replace the
		defective Products with Products that meet the warranties in clause 14.1
		at its own expense; or
	 

	 
		9.2.2
	 

	 
		where such Products have been distributed by IDIS, at GENTA’s
		discretion deduct the relevant amount from the invoice to be raised for such
		distribution or credit to IDIS’s account the purchase price invoiced and
		any applicable value added or other sales tax (where these have been paid) for
		such defective Products plus costs of carriage, insurance and other fees
		incurred by IDIS (including, without limitation, export/import duties).
	 

	 
		GENTA’s entire liability to IDIS for Products rejected for breach of
		the warranties in clause 14 or a defect or latent defect pursuant to
		clause 9.1 is limited to the remedies set out in clauses 9.1 is
		limited to the remedies set out in clauses 9.2.1 and 9.2.2.
	 

	 
		9.3
	 

	 
		Where GENTA fails to collect or request destruction of defective Products
		pursuant to clause 9.2 within fourteen (14) days, IDIS may store
		defective Products on its premises or with a third party at GENTA’s risk
		and expense.  Where GENTA fails to collect defective Products pursuant to
		clause 9.2 within thirty (30) days IDIS may destroy the defective
		Products with the consent of GENTA.
	 

	 
		9.4.
	 

	 
		Neither party shall under any circumstances be liable to the other for
		any of the types of loss listed below in this clause 9.4, whether
		arising in tort (including negligence) breach of contract, under indemnity or
		otherwise and whether or not foreseeable. Those types of loss are as follows:
	 

	 
		9.4.1
	 

	 
		loss of business or contracts;
	 

	 
		9.4.2.
	 

	 
		loss of profits;
	 

	 
		9.4.3
	 

	 
		loss of anticipated savings;
	 

	 
		9.4.4
	 

	 
		any losses which arise other than directly and naturally from a breach of
		contract or consequential, special or indirect loss.
	 

	 
		

	 

	 
		9.5.
	 

	 
		Nothing in this Agreement shall operate to exclude or restrict either
		party’s liability for death or personal injury arising from that party's
		negligence or any other liability due to that party’s fraud or any other
		liability which it is not permitted to exclude or limit as a matter of law.
	 

	 
		
 

	 

	 
		

	 

	 
		9
	 

	 
		

	 

	 
	 
		10.
	 

	 
		Payment
	 

	 
		

	 

	 
		10.1
	 

	 
		GENTA shall pay IDIS a one-time project start-up fee of * for each
		Product to be distributed pursuant to this Agreement.
	 

	 
		10.2.
	 

	 
		Within the first * Business Days of each month IDIS shall provide
		GENTA with a monthly sales report for the just concluded month which shall set
		out the product details and quantity of Products sold/supplied FOC by IDIS and
		such other information as GENTA may reasonably request.
	 

	 
		10.3
	 

	 
		Upon receipt of a monthly sales report GENTA may invoice IDIS for the
		IDIS Buy Price of the Products sold by IDIS as stated in the sales report, net
		of the applicable IDIS Fee/Pack for Products sold.
	 

	 
		10.4
	 

	 
		If IDIS’ monthly sales report includes FOC Product shipment, IDIS
		shall include an invoice to GENTA for the Fee/Pack amount due.  GENTA
		shall pay IDIS the Fee/Pack amount due within * days of the date of
		IDIS’ invoice.
	 

	 
		10.5
	 

	 
		Unless otherwise agreed, IDIS shall pay undisputed invoices within *
		days of the date of GENTA's invoice (in the currency stated on GENTA's
		invoice) by transfer to such bank account as GENTA may from time to time notify
		in writing to IDIS.
	 

	 
		10.6
	 

	 
		If an invoice is disputed by IDIS, IDIS shall pay the undisputed amount
		in accordance with clause 10.5 and the parties shall attempt to settle
		the disputed part of that invoice in accordance with clause 24.
		 Once the dispute is resolved, and if payment is due by IDIS to GENTA the
		payment shall be made within * days of the date of resolution.
	 

	 
		10.7
	 

	 
		GENTA shall provide IDIS’s request provide IDIS with a summary of
		all outstanding  invoices under clause 10.3 on or before the
		* day of each month.
	 

	 
		11
	 

	 
		Risk and Property
	 

	 
		11.1
	 

	 
		Property and risk of damage to or loss of the Products shall pass to IDIS
		on delivery.
	 

	 
		12
	 

	 
		Rights and duties of IDIS
	 

	 
		12.1
	 

	 
		During the continuance of this Agreement IDIS shall:
	 

	 
		12.1.1
	 

	 
		hold and maintain all relevant wholesale dealers and import licences and
		comply with all applicable legal and regulatory rules, laws, regulations and
		requirements in relation to each of the Products and its activities hereunder
		and in particular those relating to the storage and distribution of the
		Products in the Territory on a Named Patient Supply basis;
	 

	 
		12.1.2
	 

	 
		unless otherwise prohibited by the applicable legal and regulatory
		requirements, maintain at all times a minimum stock of Products as it shall
		reasonably require (such minimum to be agreed between the parties from time to
		time);
	 

	 
		12.1.3
	 

	 
		maintain adequate records of all supplies within the Territory
	 

	 
		12.1.4
	 

	 
		inform GENTA within two (2) business days of customer complaints,
		requirements and suggestions regarding the Products and any information which
		comes into its possession which IDIS reasonably considers may prejudice or
		enhance sales of the Products in the Territory;
	 

	 
		

	 

	 
		10
	 

	 
		

	 

	 
	 
		

	 

	 
		12.1.5
	 

	 
		inform GENTA within two (2) business days of any adverse reaction(s) to
		the Products reported to them by customers or any other person;
	 

	 
		12.1.6
	 

	 
		if GENTA or a competent regulatory authority recalls a Product, notify
		all customers who have purchased the relevant Product and in such circumstances
		and at GENTA’s expense, unless caused by the act or omission of IDIS,
		including breach of the Agreement, then at IDIS’s expense, IDIS shall
		implement a recall and arrange for the return of the recalled Products from all
		relevant customers and at GENTA’s option either return the same to GENTA
		or destroy them;
	 

	 
		12.1.7
	 

	 
		not remove the Products from the packages designed for delivery to
		customers without GENTA's prior written approval;
	 

	 
		12.1.8
	 

	 
		be entitled to describe itself as GENTA's authorised distributor of the
		Products in the Territory but shall not hold itself out as GENTA's agent;
	 

	 
		12.1.9
	 

	 
		use all commercially reasonable endeavours to control Product shipping
		costs and to deliver Products to customers using standard accepted shipping
		methods and in any event obtain GENTA’s written consent prior to incurring
		any extraordinary or substantial additional shipping cost;
	 

	 
		12.1.10
	 

	 
		promptly notify GENTA of any anticipated or actual delay in shipping
		Product to customers.
	 

	 
		13
	 

	 
		Rights and duties of GENTA
	 

	 
		13.1
	 

	 
		During the continuance of this Agreement GENTA shall:
	 

	 
		13.1.1
	 

	 
		hold and maintain all relevant licences to manufacture, assemble, package
		and label, export from the country of manufacture (if relevant) and/or supply
		the Products to IDIS pursuant to this Agreement and will comply with all
		relevant legal and regulatory requirements in relation to the manufacture,
		assembly, packaging, packing, labelling, export from the country of manufacture
		(if applicable) and/or supply of each of the Products;
	 

	 
		13.1.2
	 

	 
		notify and identify to IDIS any Product which becomes the subject of a
		Marketing Authorisation for an Indication after the Commencement Date and that
		Genta intends to launch the Product in that country;
	 

	 
		13.1.3
	 

	 
		reply to reasonable requests for information by IDIS regarding the
		Products, whether related to a technical query or otherwise, as soon as
		practicable but in any event no later than one (1) Business Day after the
		request was received;
	 

	 
		13.1.4
	 

	 
		from time to time provide IDIS with such samples, catalogues, brochures
		and up to date information (including Prices) concerning the Products as IDIS
		may reasonably require to assist IDIS with the distribution and sale of the
		Products in the Territory;
	 

	 
		13.1.5
	 

	 
		shall ensure that any price quotation regarding Products shall always
		contain its brand name, generic name, form, strength, pack size, availability
		and any other information reasonably requested by IDIS.
	 

	 
		

	 

	 
		11
	 

	 
		

	 

	 
	 
		

	 

	 
		13.2
	 

	 
		If GENTA wishes to or a competent authority requires the recall of any
		Product, GENTA shall immediately notify IDIS by telephone, fax or email (with
		confirmation in writing) of the recall, its urgency, providing details of the
		specific problem known to it, the batch number of the Products concerned and
		the details of any alternative Products and their prices that are available
		from GENTA, and IDIS shall comply with such request.  If IDIS learns of
		any such request by an authority or otherwise has reason to believe that a
		recall may be required or appropriate, it shall immediately notify GENTA.
	 

	 
		13.3
	 

	 
		In the event IDIS notifies GENTA of a reported adverse reaction(s) to a
		Product received from a customer or any other person, GENTA will henceforth
		assume responsibility for taking any and all actions relating to such adverse
		reaction(s) including, without limitation, dealing with (i) all reporting
		aspects of pharmacovigilance to the relevant competent authority, and (ii)
		allegations or findings of product and/or strict liability that may be required
		or result from an adverse reaction(s), and shall confirm to IDIS in writing
		that it has done so.
	 

	 
		13.4
	 

	 
		Provided Orders are received from IDIS in accordance with Article 6
		above, GENTA shall at all times supply IDIS with the minimum stock agreed by
		the parties pursuant to clause 12.1.2 of this Agreement.
		 Notwithstanding the above, GENTA shall use commercially reasonable
		endeavours to supply Products to IDIS in respect of orders submitted above that
		agreed threshold.
	 

	 
		13.5
	 

	 
		GENTA shall upon * days written notice to IDIS be entitled to:
	 

	 
		13.5.1
	 

	 
		discontinue or vary the manufacture and assembly and/or supply of any of
		the Products or any substance or ingredient included in the Products;
	 

	 
		13.5.2
	 

	 
		make changes in the formulation and/or composition of the Products,
	 

	 
		provided GENTA is able to supply any Orders of affected Products made by
		IDIS prior to the date of receipt by IDIS of the notice of any such
		discontinuation or variation, in their unvaried form and prior to
		discontinuation and, to the extent such Product is discontinued, GENTA may
		terminate this Agreement with respect to such Products.  
	 

	 
		14
	 

	 
		Warranties
	 

	 
		14.1
	 

	 
		GENTA accepts complete responsibility for the manufacture and assembly of
		the Products and their packaging and labelling, and represents and warrants to
		IDIS that for a period of at least until the expiry date of any Products, the
		Products shall be of merchantable quality, free from defects in composition,
		formulation, material and workmanship. 
	 

	 
		14.2
	 

	 
		GENTA represents and warrants that:
	 

	 
		14.2.1
	 

	 
		it has title to the Products;
	 

	 
		14.2.2
	 

	 
		the Products shall conform to their description, specification and data
		sheet or summary of product characteristics (if any);
	 

	 
		14.2.3
	 

	 
		the Products, their manufacture, assembly, packaging and labelling,
		export from the country of manufacture (if relevant), use, supply to IDIS and
		sale, supply or distribution of the Products in the Territory by IDIS to its
		knowledge will not infringe the Intellectual Property Rights of any third
		party;
	 

	 
		

	 

	 
		12
	 

	 
		

	 

	 
	 
		

	 

	 
		14.2.4
	 

	 
		it is authorised to manufacture, assemble, package and label, export from
		the country of manufacture (if applicable) and supply the Products to IDIS for
		IDIS to distribute on a Named Patient Supply basis within the Territory.
	 

	 
		14.3
	 

	 
		IDIS represents and warrants to GENTA that it is authorised to sell,
		supply and distribute the Products in the Territory on a Named Patient Supply
		basis, where permitted, in each country within the Territory as set out in
		Schedule 2.
	 

	 
		14.4
	 

	 
		Each party represents and warrants to the other that it will comply with
		its obligations set out in the Service Level Agreement and the Technical
		Agreement.
	 

	 
		14.5
	 

	 
		EXCEPT AS PROVIDED UNDER CLAUSES 14.1 AND 14.2, GENTA
		SPECIFICALLY DISCLAIMS ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING
		BUT NOT LIMITED TO ANY WARRANTY OF MERCHANTABILITY, NON-INFRINGEMENT, AND
		FITNESS FOR A PARTICULAR PURPOSE.  GENTA MAKES NO REPRESENTATION OR
		WARRANTY OF COMMERCIAL VIABILITY OR SUCCESS OF THE PRODUCTS.
	 

	 
		15
	 

	 
		Indemnities
	 

	 
		15.1
	 

	 
		GENTA shall indemnify IDIS in respect of:
	 

	 
		15.1.1
	 

	 
		the manufacture and assembly, packaging and labelling of the Products;
	 

	 
		15.1.2
	 

	 
		failure to provide any information required to be provided by GENTA to
		IDIS under the terms of this Agreement within the applicable time frame.
	 

	 
		15.2
	 

	 
		GENTA shall indemnify IDIS in respect of any allegation or finding that
		the sale of Products by IDIS in the Territory infringes the Intellectual
		Property Rights of any third party or any rights of any third party unless such
		allegation or finding is attributable to any mark or method of packaging or get
		up of the Product or written material or directions relating to the Product
		applied, used or given by IDIS otherwise than as directed by GENTA.
	 

	 
		15.3
	 

	 
		Each party shall indemnify the other party in respect of any breach by it
		of that party’s representations and warranties given in this Agreement.
	 

	 
		15.4
	 

	 
		The indemnities contained in clauses 15.1, 15.2 and
		15.3 above shall be conditional in each case upon the indemnified party:

	 

	 
		15.4.1
	 

	 
		promptly giving written notice of any claim to be indemnified to the
		indemnifying party;
	 

	 
		15.4.2
	 

	 
		providing the indemnifying party with the absolute discretion to conduct,
		take or resist any proceedings as it sees fit at its own expense;
	 

	 
		15.4.3
	 

	 
		providing the indemnifying party on request with such information and
		assistance in relation to such proceedings as it may reasonably require,
		subject to the indemnifying party indemnifying the other party against all
		costs reasonably incurred by it in the provision of such information or
		assistance; and
	 

	 
		

	 

	 
		13
	 

	 
		

	 

	 
	 
		

	 

	 
		15.4.4
	 

	 
		does not make any settlement, compromise or prejudicial admission in
		relation to such claim without the prior consent of the indemnifying party
		(such consent not to be unreasonably withheld or delayed).
	 

	 
		16
	 

	 
		Intellectual Property 
	 

	 
		16.1
	 

	 
		GENTA grants IDIS a royalty free licence to use the Trade Marks in the
		Territory on or in relation to the Products for the purposes only of exercising
		its rights and performing its obligations under this Agreement (including,
		without limitation, distributing and selling the Products).
	 

	 
		16.2
	 

	 
		IDIS shall not without the prior written consent of GENTA:
	 

	 
		16.2.1
	 

	 
		make any modifications to the Products or their packaging or labelling;
	 

	 
		16.2.2
	 

	 
		alter, remove or tamper with any Trade Marks, numbers, or other means of
		identification used on or in relation to the Products;
	 

	 
		16.2.3
	 

	 
		use any of the Trade Marks in any way which might prejudice their
		distinctiveness or validity or the goodwill of GENTA therein; or
	 

	 
		16.2.4
	 

	 
		use in relation to the Products any trade marks other than the Trade
		Marks without obtaining the prior written consent of GENTA.
	 

	 
		16.3
	 

	 
		Except as provided in this Agreement, IDIS shall have no rights in
		respect of any trade names or Trade Marks used by GENTA in relation to the
		Products or of the goodwill associated therewith, and IDIS hereby acknowledges
		that, except as expressly provided in this agreement, it shall not acquire any
		rights in respect of any trade names or Trade Marks and that all such rights
		and goodwill are, and shall remain, vested in GENTA.
	 

	 
		16.4
	 

	 
		IDIS shall, at the expense of GENTA, take all such steps as GENTA may
		reasonably require to assist GENTA in maintaining the validity and
		enforceability of the Intellectual Property Rights of GENTA during the
		continuance of this Agreement.
	 

	 
		16.5
	 

	 
		Without prejudice to the rights of IDIS or any third party to challenge
		the validity of any Intellectual Property Rights of GENTA, IDIS shall not
		knowingly do or authorise any third party to do any act which would invalidate
		or be inconsistent with any Intellectual Property Rights of GENTA and shall not
		knowingly omit or authorise any third party to omit to do any act which, by its
		omission, would have that effect or character.
	 

	 
		16.6
	 

	 
		Without prejudice to clause 15.2, IDIS shall notify GENTA of any
		actual or threatened infringement in the Territory of any Intellectual Property
		Rights of GENTA which comes to IDIS’s notice, and of any claim by any
		third party so coming to its notice that the importation of the Products into
		the Territory, or their sale in the Territory, infringes any rights of any
		other person, and IDIS shall at the request and expense of GENTA do all such
		things as may be reasonably required to assist GENTA in taking or resisting any
		proceedings in relation to any such infringement or claim.
	 

	 
		17
	 

	 
		Termination
	 

	 
		17.1
	 

	 
		GENTA may terminate this Agreement in respect of any or all Products in
		any or all countries of the Territory for any reason by giving not less than
		* days written notice to IDIS to that effect.  The Agreement shall
		continue in effect with respect to any un-terminated Products in any
		un-terminated country.  Upon termination of all Products in all countries,
		this Agreement shall terminate in its entirety.
	 

	 
		

	 

	 
		14
	 

	 
		

	 

	 
	 
		

	 

	 
		17.2
	 

	 
		Before or after the expiry of the Term, as the case may be, either party
		shall have the right to terminate this Agreement immediately by notice to the
		other if the other party:
	 

	 
		17.2.1
	 

	 
		commits any material or persistent breach of any of the provisions of
		this Agreement and, in the case of a breach capable of remedy, that party fails
		to remedy such breach within * days after receipt of a notice giving
		full particulars of the breach and requiring it to be remedied;
	 

	 
		17.2.2
	 

	 
		being a company, summons a meeting of its creditors, makes a proposal for
		a voluntary arrangement, becomes subject to any voluntary arrangement, is
		unable to pay its debts within the meaning of section 123 Insolvency
		Act 1986, has a receiver, manager or administrative receiver appointed
		over any of its assets, undertakings or income, has passed a resolution for its
		winding-up (save for the purpose of a voluntary reconstruction or amalgamation
		previously approved in writing by the party serving notice), is subject to a
		petition presented to any Court for its winding-up (save for the purpose of a
		voluntary reconstruction or amalgamation previously approved in writing by the
		party serving notice), has a provisional liquidator appointed, has a proposal
		made for a scheme of arrangement under section 425 Companies Act 1985, has an
		administrator appointed in respect of it or is the subject of an application
		for administration filed at any court or a notice of appointment of an
		administrator filed at any court or a notice of intention to appoint an
		administrator given by any person or is the subject of a notice to strike off
		the register at Companies House or any of the foregoing ;
	 

	 
		17.2.3
	 

	 
		the other party has any distrait, execution or other process levied or
		enforced on any of its property;
	 

	 
		17.2.4
	 

	 
		the other party ceases, or threatens to cease to carry on business;
	 

	 
		17.2.5
	 

	 
		has any proceedings analogous to those referred to in clauses
		17.2.2 to 17.2.4 occur in relation to the other party or its assets
		in accordance with the jurisdiction to which the other party or its assets are
		subject;
	 

	 
		17.2.6
	 

	 
		in the circumstances contemplated by clause 24.3 where there is no
		agreement reached by the parties within * days after discussions for
		that purpose began or ought to have begun.
	 

	 
		17.3
	 

	 
		For the purposes of clause 17.2.1 a breach shall be considered
		capable of remedy if the party in breach can comply with the provision in
		question in all respects save as to the time of performance (provided that time
		of performance is not of the essence).
	 

	 
		17.4
	 

	 
		The rights to terminate this Agreement given by clause 17.2 shall
		be without prejudice to any other right or remedy of either party in respect of
		the breach concerned (if any) or any other breach.
	 

	 
		

	 

	 
		15
	 

	 
		

	 

	 
	 
		18
	 

	 
		Consequences of termination 
	 

	 
		18.1
	 

	 
		Upon termination of this Agreement for any reason:
	 

	 
		

	 

	 
		18.1.1
	 

	 
		save as otherwise agreed, including, without limitation, to effect
		clause 18.1.2, IDIS shall immediately cease to make use of the Trade
		Marks;
	 

	 
		18.1.2
	 

	 
		IDIS shall be entitled to complete all Orders placed with and accepted in
		the entirety by GENTA prior to the date of termination;
	 

	 
		18.1.3
	 

	 
		at the request of a party and at that party’s expense, the other
		party shall return or destroy any Confidential Information provided by the
		first party;
	 

	 
		18.1.4
	 

	 
		IDIS shall have no claim against GENTA for loss of distribution rights,
		goodwill or other similar loss;
	 

	 
		18.1.5
	 

	 
		IDIS’s rights hereunder shall immediately end.
	 

	 
		18.2
	 

	 
		In the event of termination by either party or GENTA under clause
		17.1, 17.2.1 or 17.4:
	 

	 
		18.2.1
	 

	 
		IDIS shall, if GENTA so requests, within * days of the date of
		termination of this Agreement return all or any part of the stocks of the
		Products then held by IDIS to GENTA at GENTA’s cost of transportation and
		insurance, and risk.  IDIS shall be responsible for arranging
		transportation and insurance;   
	 

	 
		18.2.2
	 

	 
		IDIS shall be entitled to sell all remaining stocks that GENTA does not
		wish to reclaim under clause 18.2.1 and for those purposes and to that
		extent, the provisions of this Agreement shall continue in full force and
		effect.
	 

	 
		18.3
	 

	 
		In the event of termination by IDIS under clause 17.2.1 IDIS may
		at its option:
	 

	 
		18.3.1
	 

	 
		within * days of the date of termination of this Agreement require
		GENTA to collect all or any part of the stocks of the Products then held by
		IDIS at GENTA’s cost of transportation and insurance and risk.  IDIS
		shall be responsible for arranging transportation and insurance;
	 

	 
		18.3.2
	 

	 
		sell all or any remaining stocks GENTA is not required to collect under
		clause 18.3.1 and for those purposes and to that extent, the provisions
		of this Agreement shall continue in full force and effect.
	 

	 
		18.4
	 

	 
		In the event of termination of this Agreement in its entirety for either
		Ganite or Genasense by GENTA under clause 17.1 prior to expiration of
		the  Term, GENTA shall pay to IDIS a termination fee of * for
		either drug (or * for termination of both Ganite and Genasense)
		multiplied by the total number of months remaining in the Term, up to a maximum
		of * months. For clarity, the maximum payment under this clause
		18.4 shall be * for termination with respect to one Product or
		* for termination of the Agreement with respect to both Products.
	 

	 
		18.5
	 

	 
		Clauses 14, 15, 18, 19, 22 and 23
		shall survive termination of this Agreement.
	 

	 
		19
	 

	 
		Confidential Information
	 

	 
		19.1
	 

	 
		With respect to Confidential Information received by a party from the
		other party after the Commencement Date, except as provided by clauses
		19.2 and 19.3, each party shall at all times during the continuance
		of this Agreement and for * years after its termination:
	 

	 
		

	 

	 
		16
	 

	 
		

	 

	 
	 
		

	 

	 
		19.1.1
	 

	 
		use its best endeavours to keep all Confidential Information of the other
		party secret and confidential and accordingly not disclose any Confidential
		Information of the other party to any other person; and
	 

	 
		19.1.2
	 

	 
		not use any Confidential Information of the other party for any purpose
		other than for the performance of its obligations under this Agreement.
	 

	 
		19.2
	 

	 
		Any Confidential Information may be disclosed by a party to:
	 

	 
		19.2.1
	 

	 
		any governmental or relevant competent authority pursuant to a statutory
		or regulatory requirement but then only to the extent of such required
		disclosure;
	 

	 
		19.2.2
	 

	 
		its professional advisers, lawyers, auditors and bankers under
		obligations of confidentiality; or
	 

	 
		19.2.3
	 

	 
		any of its directors or employees or of any of the aforementioned
		persons, to such extent only as is necessary for the purposes contemplated by
		this Agreement, or as is required by law and subject in each case to that party
		ensuring that the person in question keeps the same confidential and does not
		use the same except for the purposes of this Agreement.
	 

	 
		19.3
	 

	 
		Any Confidential Information may be used by a party for any purpose, or
		disclosed to any other person, to the extent only that:
	 

	 
		19.3.1
	 

	 
		it is on the Commencement Date, or later becomes, public knowledge
		through no fault of that party;
	 

	 
		19.3.2
	 

	 
		it can be shown by that party, to the reasonable satisfaction of the
		other party, to have been known to the first party other than as a result of a
		breach of this clause 19 prior to the same being disclosed by the other
		party to the first party;
	 

	 
		19.3.3
	 

	 
		the information has been lawfully obtained after the Commencement Date
		from a third party free of any duty of confidentiality;
	 

	 
		19.3.4
	 

	 
		the other party has given its prior written consent to such use and/or
		disclosure; or
	 

	 
		19.3.5
	 

	 
		the information was independently developed by that party.
	 

	 
		19.4
	 

	 
		Notwithstanding this clause 19, GENTA and IDIS shall be free to
		use for any purpose the general knowledge resulting from access to work with or
		exposure to the other party’s Confidential Information, provided that such
		party shall maintain the confidentiality of the Confidential Information as
		provided herein and this provision shall not be deemed a license of either
		party’s Intellectual Property Rights.  The term “general
		knowledge” means information in non-tangible form which may be retained by
		persons who have had access to Confidential Information of the other party,
		including ideas, concepts, know-how or techniques contained therein.
	 

	 
		20
	 

	 
		Data Protection
	 

	 
		20.1
	 

	 
		Each Party shall comply at all times with all applicable European and/or
		national data protection Laws including but not limited to the EC Directive
		94/46EC (collectively, the “Data Protection Laws”) in relation to
		personal information (as defined by Data Protection Laws) that is held or
		processed by the parties in the course of performing their obligations under
		this Agreement.
	 

	 
		

	 

	 
		17
	 

	 
		

	 

	 
	 
		

	 

	 
		20.2
	 

	 
		No transfers of personal information processed or controlled by either
		party will be made from within the European Economic Area to any country
		outside of the European Economic Area unless such country is a country that has
		been recognized by the European Commission as providing adequate protection of
		personal information or unless the parties have entered into the model contract
		approved by the European Commission found at http://www.europa.eu/justice_home/fsj/privacy/modelcontracts/index-en.htm

	 

	 
		

	 

	 
		21
	 

	 
		Force Majeure
	 

	 
		21.1
	 

	 
		If either party is affected by Force Majeure it shall forthwith notify
		the other party of the nature and extent thereof.
	 

	 
		21.2
	 

	 
		Neither party shall be deemed to be in breach of this Agreement, or
		otherwise be liable to the other, by reason of any delay in performance, or
		non-performance, of any of its obligations under this Agreement to the extent
		that such delay or non-performance is due to any Force Majeure of which it has
		notified the other party, and the time for performance of that obligation shall
		be extended accordingly.
	 

	 
		21.3
	 

	 
		If the Force Majeure in question prevails for a continuous period in
		excess of three months, the parties shall enter into bona fide discussions with
		a view to alleviating its effects, or to agreeing upon such alternative
		arrangements as may be fair and reasonable in the circumstances.
	 

	 
		22
	 

	 
		Notice
	 

	 
		22.1
	 

	 
		Any notice to be served by one party on the other shall be in writing and
		shall be served by sending it by pre-paid recorded delivery (or by pre-paid
		registered air mail where appropriate) to the Service Address or by fax to the
		Fax Address or to such other address as is notified by that party to the other
		from time to time in accordance with this clause 22.
	 

	 
		22.2
	 

	 
		Notice shall be deemed received in the case of pre-paid recorded
		delivery, two (2) days from the date of posting, in the case of
		registered airmail, five (5) days from the date of posting, and in the
		case of fax, at the time of transmission.
	 

	 
		22.3
	 

	 
		In proving service it shall be sufficient to prove that the envelope
		containing such notice was correctly addressed and delivered or the notice was
		transmitted by fax to the Fax Address and a successful transmission sheet
		exists.
	 

	 
		23
	 

	 
		General
	 

	 
		23.1
	 

	 
		Neither party shall without the prior written consent of the other
		sub-contract, assign or transfer, or purport to sub-contract, assign or
		transfer to any other person any of its rights or obligations under this
		Agreement without the prior written consent of the other party, provided that
		GENTA may assign this Agreement in its entirety without the consent of IDIS to
		an affiliate or to a purchaser of all or substantially all of its assets to
		which this Agreement relates.   save that this Agreement will be
		binding upon and inure to any successor(s) to the business of either party.
	 

	 
		

	 

	 
		18
	 

	 
		

	 

	 
	 
		

	 

	 
		23.2
	 

	 
		Neither party nor its agents or employees shall be deemed to be an agent
		of the other for any purpose whatsoever, and neither party shall have, nor
		shall it represent itself as having, any authority to make contracts or
		obligations in the name of or binding upon the other party, to pledge the other
		party’s credit, or to extend credit to anyone in the other party’s
		name.
	 

	 
		23.3
	 

	 
		This Agreement and the documents referred to in it, including
		Confidentiality Agreements, contains the entire agreement between the parties
		in respect of the subject matter of the Agreement, and supersede all prior
		written or oral agreements, representations or understandings between the
		parties in respect thereto. The parties acknowledge that this Agreement has not
		been entered into wholly or partly in reliance on, nor has either party been
		given any warranty, statement, promise or representation made by or on their
		behalf other than as expressly set out in this Agreement.  To the extent
		that any such warranties, statements, promises or representations have been
		given the recipient party unconditionally and irrevocably waives any claims,
		rights or remedies which it might otherwise have had in relation to them.
		Nothing in this clause 23.3 will exclude any liability which one party
		would otherwise have to the other party in respect of any statements made
		fraudulently.
	 

	 
		23.4
	 

	 
		This Agreement may not be modified except in writing signed by the duly
		authorised representatives of each party.
	 

	 
		23.5
	 

	 
		In the event that any of the provisions of this Agreement or the
		application of any such provisions to the parties shall be held by a court of
		competent jurisdiction to be contrary to law, the remaining portions of this
		Agreement shall remain in full force and effect.
	 

	 
		23.6
	 

	 
		The failure or delay by either party to this Agreement in exercising any
		right, power or remedy of that party under this Agreement will not in any
		circumstances impair such right, power or remedy nor operate as a waiver of it.
		 The single or partial exercise by either party to this Agreement of any
		right, power or remedy under this Agreement will not in any circumstances
		preclude any other or further exercise of it or the exercise of any other
		right, power or remedy.
	 

	 
		23.7
	 

	 
		Except as expressly provided in this Agreement, the rights, powers and
		remedies provided in this Agreement are cumulative and not exclusive of any
		rights, powers and remedies provided by law.
	 

	 
		23.8
	 

	 
		No waiver by either party of any breach of this Agreement by the other
		shall be considered as a waiver of any subsequent breach of the same or any
		other provisions.
	 

	 
		23.9
	 

	 
		The parties to this Agreement do not intend that any of its terms will be
		enforceable by virtue of the Contracts (Rights of Third Parties) Act 1999 by
		any person not a party to it.
	 

	 
		23.10
	 

	 
		This Agreement may be executed in any number of counterparts, each of
		which when executed shall be construed as an original, but together will
		constitute one and the same instrument.
	 

	 
		23.11
	 

	 
		During the continuance of this Agreement and for * years after
		termination of this Agreement in its entirety, IDIS shall make available to
		GENTA any financial records specifically relating to activities under this
		Agreement that GENTA reasonably requests to determine whether IDIS has complied
		with the terms and provisions of this Agreement.
	 

	 
		

	 

	 
		19
	 

	 
		

	 

	 
	 
		

	 

	 
		24
	 

	 
		Disputes
	 

	 
		24.1
	 

	 
		Subject to clause 25, if any dispute arises out of this Agreement,
		in the first instance, the parties’ account managers shall attempt to
		resolve the dispute amicably within * days.
	 

	 
		24.2
	 

	 
		If a dispute cannot be resolved by the parties’ account managers,
		the parties shall promptly refer the matter to their respective Chief Executive
		Officers. If either party refuses to make such referral or participate in good
		faith in this dispute resolution procedure and in any event, if the dispute is
		not resolved within * days of such referral or the date such referral
		could have been made, then either party may commence proceedings in accordance
		with clause 25.
	 

	 
		24.3
	 

	 
		Where either party reasonably believes that a dispute relates to a
		material breach or potential breach of this Agreement or a Contract, that party
		shall notify its and the other party’s account managers and each party
		shall then refer the dispute directly to their Chief Executive Officers and the
		provisions of clause 24.2 shall apply.
	 

	 
		25
	 

	 
		Governing Law and Jurisdiction
	 

	 
		25.1
	 

	 
		This Agreement shall be governed by, and construed in all respects in
		accordance with the laws of England.
	 

	 
		25.2
	 

	 
		Subject to clause 24, the courts of England will have exclusive
		jurisdiction to settle any disputes which may arise out of or in connection
		with this Agreement.  The parties irrevocably agree to submit to that
		jurisdiction except that either party may seek injunctive relief in any court
		of competent jurisdiction.
	 

	 
		

	 

	 
		20
	 

	 
		

	 

	 
	 
		

	 

	 
		

	 

	 
		

	 

	 
		IN WITNESS of which the parties have signed this Agreement on the date
		set out above.
	 

	 
		

	 

	 
		

	 

	 		
	
			 
				SIGNED for and on behalf of
			 

		  	
			 
				 
			 

		  
	
			 
				GENTA INCORPORATED
			 

		  	
			 
				 
			 

		  
	
			 
				by [RICHARD J. MORAN]
			 

		  	
			 
				 
			 

		  
	
			 
				 
			 

		  	
			 
				[Chief Financial Officer, Secretary & Treasurer]
			 

		  
	
			 
				 
			 

		  	
			 
				 
			 

		  
	
			 
				SIGNED for and on behalf of IDIS
			 

		  	
			 
				 
			 

		  
	
			 
				by [ Natalie Douglas]
			 

		  	
			 
				 
			 

		  
	
			 
				 
			 

		  	
			 
				[Managing Director ]
			 

		  

	 
		

	 

	 
		21
	 

	 
		

	 

	 
	 
		

	 

	 
		SCHEDULE 1
	 

	 
		

	 

	 
		Products
	 

	 
		

	 

	 
		

	 

	 
		

	 

	 									
	
			 
				Fee Structure for
				Genasense®
			 

		  
	
			 
				# Packs Sold
			 

			 
				by IDIS
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  
	
			 
				IDIS Buy  Price
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  
	
			 
				IDIS Fee/Pack
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  
	
			 
				IDIS %Fee/Pack
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  	
			 
				*
			 

		  

	 
		

	 

	 
		

	 

	 
		

	 

	 		
	
			 
				Fee Structure for Ganite®
			 

		  
	
			 
				 
			 

		  	
			 
				Per Pack Sold
			 

			 
				by IDIS
			 

		  
	
			 
				IDIS Buy Price
			 

		  	
			 
				*
			 

		  
	
			 
				IDIS Fee/Pack
			 

		  	

			 
				*
			 

		  
	
			 
				IDIS %Fee/Pack
			 

		  	
			 
				*
			 

		  

	 
		

	 

	 
		All prices are in US Dollars ($)
	 

	 
		

	 

	 
		GENTA will supply only full packs (containing five vials) to IDIS and
		IDIS may sell only full packs containing five vials.  Sale of individual
		vials or partial packs is not permitted.
	 

	 
		

	 

	 
		Carriage to be charged onto end customer in the territory
	 

	 
		

	 

	 
		For purposes of determining the applicable IDIS Fee/Pack for Genasense, #
		Packs Sold by IDIS will be cumulative over the Term.
	 

	 
		

	 

	 
		For clarity, assuming 1,000 packs of Genasense are sold within the Term,
		the IDIS fee shall total *.
	 

	 
		

	 

	 
		22
	 

	 
		

	 

	 
	 
		

	 

	 
		SCHEDULE 2
	 

	 
		

	 

	 
		Territory
	 

	 
		

	 

	 
		

	 

	 
		Worldwide
	 

	 
		

	 

	 
		With the exception of 
	 

	 
		

	 

	 
		

	 

	 
		Cuba
	 

	 
		Iran 
	 

	 
		Libya
	 

	 
		The Sudan
	 

	 
		USA
	 

	 
		

	 

	 
		

	 

	 
		
 

	 

	 
		

	 

	 
		23
	 

	 
		

	 

	 
	 
		

	 

	 
		

	 

	 
		

	 

	 
		SCHEDULE 3
	 

	 
		

	 

	 
		Trade Marks
	 

	 
		

	 

	 
		

	 

	 
		

	 

	 
		Ganite®
	 

	 
		

	 

	 
		Genasense®
	 

	 
		

	 

	 
		Genta®
	 

	 
		

	 

	 
		

	 

	 
	 
		

	 

	 
	 
		

	 

	 
		

	 

	 
		

	 

	 
		24
	 

	 
		

	 

	 
	 
		

	 

	 
		 SCHEDULE 4
	 

	 
		

	 

	 
		Service
	 

	 
		

	 

	 
		

	 

	 		
	
			 
				GENTA’s Service Address
			 

			 
				

			 

			 
				

			 

		  	
			 
				200 Connell Drive
			 

			 
				Berkeley Heights, NJ  07922
			 

			 
				USA
			 

			 
				

			 

			 
				

			 

			 
				

			 

		  
	
			 
				GENTA’s Telephone Number(s)
			 

			 
				

			 

		  	
			 
				+1 (908) 286-9800
			 

		  
	
			 
				GENTA’s Fax Address
			 

			 
				

			 

		  	
			 
				+1 (908) 464-1701
			 

		  
	
			 
				IDIS’s Service Address 
			 

			 
				

			 

			 
				

			 

		  	
			 
				IDIS House
			 

			 
				Churchfield Road
			 

			 
				Weybridge
			 

			 
				Surrey  
			 

			 
				KT13 8DB
			 

			 
				United Kingdom
			 

		  
	
			 
				IDIS’s Telephone Number(s)
			 

			 
				

			 

		  	
			 
				[+44 1932 824100]
			 

		  
	
			 
				IDIS’s Fax Address
			 

			 
				

			 

		  	
			 
				[+44 1932 824200]
			 

		  

	 
		

	 

	 
		

	 

	 
		25
	 

	 
		

	 

	 
	 
		

	 

	 
		 SCHEDULE 5
	 

	 
		

	 

	 
		Technical Agreement
	 

	 
		

	 

	 
		

	 

	 
		EXECUTED AS A SEPARATE AGREEMENT BETWEEN IDIS AND GENTA
	 

	 
		
 

	 

	 
		

	 

	 
		26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]